MoonLake Immunotherapeutics gains on smaller-than-expected Q1 loss

MoonLake Immunotherapeutics

12/05/2023 19:05

** Shares of Switzerland-based MoonLake Immunotherapeutics
 MLTX.O  up 2.1% at $27.27
    ** Co reports net loss of 23 cents/share in Q1, beating
analysts' estimated loss of 31 cents/share - Refinitiv data
    ** As of March 31, MLTX held cash, cash equivalents and
short-term marketable debt securities of $63.1 mln
    ** Expected cash runway extended to the end of 2024
    ** Shares up ~160% YTD

 (Reporting by Yamini Kalia in Bengaluru)
 ((Yamini.Kalia@thomsonreuters.com))